Literature DB >> 30208508

Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.

M Frodlund1, A Vikerfors2, G Grosso2, T Skogh1, J Wetterö1, K Elvin3, I Gunnarsson2, A Kastbom1, Ö Dahlström4, J Rönnelid5, E Svenungsson2, C Sjöwall1.   

Abstract

Immunoglobulin (Ig) G- and IgM-class anti-cardiolipin antibodies (aCL) and lupus anti-coagulant (LA) are included in the 1997 update of the American College of Rheumatology (ACR-97) systemic lupus erythematosus (SLE) criteria. Despite limited evidence, IgA-aCL and IgA anti-β2 -glycoprotein-I (anti-β2 GPI) were included in the 2012 Systemic Lupus International Collaborating Clinics criteria. The present study aimed to evaluate IgG-/IgA-/IgM-aCL and anti-β2 GPI occurrence in relation to disease phenotype, smoking habits, pharmacotherapy, anti-phospholipid syndrome (APS) and organ damage among 526 Swedish SLE patients meeting ACR-97. Patients with rheumatoid arthritis (n = 100), primary Sjögren's syndrome (n = 50) and blood donors (n = 507) served as controls. Anti-phospholipid antibodies (aPL) were analysed by fluoroenzyme-immunoassays detecting aCL/anti-β2 GPI. Seventy-six (14%) SLE cases fulfilled the Sydney APS-criteria, and ≥ 1 aCL/anti-β2 GPI isotype (IgG/IgA/IgM) occurred in 138 SLE patients (26%). Forty-five (9%) of the SLE cases had IgA-aCL, 20 of whom (4%) lacked IgG-/IgM-aCL. Seventy-four (14%) tested positive for IgA anti-β2 GPI, 34 (6%) being seronegative regarding IgG/IgM anti-β2 GPI. Six (1%) had APS manifestations but were seropositive regarding IgA-aCL and/or IgA anti-β2 GPI in the absence of IgG/IgM-aPL and LA. Positive LA and IgG-aPL tests were associated with most APS-related events and organ damage. Exclusive IgA anti-β2 GPI occurrence associated inversely with Caucasian ethnicity [odds ratio (OR) = 0·21, 95% confidence interval (CI) = 0·06-0·72) and photosensitivity (OR = 0·19, 95% CI = 0·05-0·72). Nephritis, smoking, LA-positivity and statin/corticosteroid-medication associated strongly with organ damage, whereas hydroxychloroquine-medication was protective. In conclusion, IgA-aPL is not rare in SLE (16%) and IgA-aPL analysis may have additional value among SLE cases with suspected APS testing negative for other isotypes of aPL and LA.
© 2018 British Society for Immunology.

Entities:  

Keywords:  anti-phospholipid antibodies; anti-phospholipid syndrome; autoantibodies; immunoglobulin A; systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 30208508      PMCID: PMC6156819          DOI: 10.1111/cei.13180

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  54 in total

1.  Stroke in systemic lupus erythematosus: a Swedish population-based cohort study.

Authors:  Elizabeth V Arkema; Elisabet Svenungsson; Mia Von Euler; Christopher Sjöwall; Julia F Simard
Journal:  Ann Rheum Dis       Date:  2017-04-11       Impact factor: 19.103

2.  IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome.

Authors:  Elena Mattia; Amelia Ruffatti; Marta Tonello; Lauro Meneghel; Bianca Robecchi; Marina Pittoni; Nicoletta Gallo; Elisa Salvan; Vera Teghil; Leonardo Punzi; Mario Plebani
Journal:  Clin Chem Lab Med       Date:  2014-09       Impact factor: 3.694

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 4.  Systemic lupus erythematosus.

Authors:  Larissa Lisnevskaia; Grainne Murphy; David Isenberg
Journal:  Lancet       Date:  2014-05-31       Impact factor: 79.321

Review 5.  Antiphospholipid antibody testing and standardization.

Authors:  K M J Devreese
Journal:  Int J Lab Hematol       Date:  2014-06       Impact factor: 2.877

6.  Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry.

Authors:  M J Gonçalves; S Sousa; L S Inês; C Duarte; J Borges; C Silva; V C Romão; G Terroso; M Bernardes; M Cerqueira; A Raposo; G Sequeira; A Barcelos; C Macieira; J Canas da Silva; L Costa; J A Pereira da Silva; L Cunha-Miranda; J A P Da Silva; H Canhão; M J Santos
Journal:  Lupus       Date:  2014-10-15       Impact factor: 2.911

Review 7.  Patterns of systemic lupus erythematosus expression in Europe.

Authors:  R Cervera; A Doria; Z Amoura; M Khamashta; M Schneider; F Guillemin; F Maurel; A Garofano; M Roset; A Perna; M Murray; C Schmitt; I Boucot
Journal:  Autoimmun Rev       Date:  2014-01-10       Impact factor: 9.754

Review 8.  The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis.

Authors:  Ewa Olech; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 9.  Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects.

Authors:  Anna Nuttall; David A Isenberg
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-10-05       Impact factor: 4.098

10.  Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients.

Authors:  Laura Despierres; Abdou Beziane; Gilles Kaplanski; Brigitte Granel; Jacques Serratrice; William Cohen; Florence Bretelle; Pascal Rossi; Pierre-Emmanuel Morange; Pierre Jean Weiller; Jean Robert Harlé; Pierre Bongrand; Nathalie Bardin
Journal:  Rheumatology (Oxford)       Date:  2014-03-04       Impact factor: 7.580

View more
  6 in total

1.  Variation of Complement Protein Levels in Maternal Plasma and Umbilical Cord Blood during Normal Pregnancy: An Observational Study.

Authors:  Muna Saleh; Michele Compagno; Sofia Pihl; Helena Strevens; Barbro Persson; Jonas Wetterö; Bo Nilsson; Christopher Sjöwall
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

Review 2.  The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome.

Authors:  Oscar Cabrera-Marante; Edgard Rodríguez de Frías; Manuel Serrano; Fernando Lozano Morillo; Laura Naranjo; Francisco J Gil-Etayo; Estela Paz-Artal; Daniel E Pleguezuelo; Antonio Serrano
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

3.  Longitudinal Analysis of Anti-cardiolipin and Anti-β2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients.

Authors:  Martina Frodlund; Tomas Walhelm; Charlotte Dahle; Christopher Sjöwall
Journal:  Front Med (Lausanne)       Date:  2021-02-24

4.  IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus.

Authors:  Tatiana Reshetnyak; Fariza Cheldieva; Maria Cherkasova; Alexander Lila; Evgeny Nasonov
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

5.  High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients.

Authors:  Sahwa Elbagir; Amir I Elshafie; Elnour M Elagib; NasrEldeen A Mohammed; Mawahib Ie Aledrissy; Vivek Anand Manivel; Eleftheria Pertsinidou; Musa Am Nur; Iva Gunnarsson; Elisabet Svenungsson; Johan Rönnelid
Journal:  Lupus       Date:  2020-08-02       Impact factor: 2.911

6.  Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population.

Authors:  Chaojun Hu; Xi Li; Jiuliang Zhao; Qian Wang; Mengtao Li; Xinping Tian; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2020-10-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.